Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Comprehensive Dosing Guide
What to Monitor
For Diabetes:
- Check your blood sugar levels regularly.
- Have your HbA1c (a measure of blood sugar control) checked every 3 months.
- Watch for signs of low blood sugar, especially if you're also taking insulin or other diabetes meds.
For Weight Loss:
- Keep track of your weight loss.
- Check for any nutritional deficiencies.
- Watch for any side effects regularly.
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.